Novavax Reports First Quarter 2026 Financial Results and Operational Highlights

About this update from Novavax, Inc.

[{"type":"list","items":[{"val":[{"type":"text","content":"Total revenue of $140 million in the first quarter of 2026","length":58,"tagName":"p"}]},{"val":[{"type":"text","content":"Pfizer agreement announced in January for non-exclusive license to utilize Matrix-M® in two infectious disease areas","length":166,"tagName":"p"}]},{"val":[{"type":"text","content":"In April, Novavax signed a new MTA with a top 10 leading pharmaceutical company and leader in oncology to explore Matrix-M in multiple oncology and infectious disease targets ","length":174,"tagName":"p"}]},{"val":[{"type":"text","content":"In April, Novavax expanded an existing partnership with a new MTA, providing access to Matrix-M for exploration in up to nine additional identified infectious diseases","length":167,"tagName":"p"}]},{"val":[{"type":"text","content":"In February, Novavax expanded an existing MTA with a major global pharmaceutical company to explore an additional field and signed a new MTA with an oncology company","length":165,"tagName":"p"}]},{"val":[{"type":"text","content":"Sanofi announced positive results from the Phase 4 COMPARE study, a head-to-head study comparing Nuvaxovid™ and Moderna's mNEXSPIKE that reinforces Nuvaxovid's well established and differentiated reactogenicity profile","length":226,"tagName":"p"}]},{"val":[{"type":"text","content":"Novavax's C. difficile vaccine candidate prioritized with potential to enter the clinic as early as 2027","length":108,"tagName":"p"}]},{"val":[{"type":"text","content":"Reiterates 2026 Revenue Framework and Combined R&D and SG&A expense guidance ","length":84,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":1148,"olType":false},{"type":"text","content":"GAITHERSBURG, Md., May 6, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the first quarter ended March 31, 2026.","length":184,"tagName":"p"},{"type":"text","content":""Novavax continued to make significant progress executing our corporate strategy, which is comprised of partnering our technology, capital-efficient R&D innovation and a lean operating platform. In 2026, we signed a new, Matrix-M license with Pfizer for up to two vaccine candidates and secured four additional MTAs with a growing list of large pharmaceut...

More updates from Novavax, Inc.